Results regarding the frequency of CDKN2A promoter methylation are inconsistent in prostate tumors, ranging from 3% to 77%; other studies have investigated the role of hypermethylated CDKN2A in the carcinogenesis and progression of PCa [45, 47, 79-85]. The gene discussed is CDKN2A; the disease is posterior cortical atrophy.